亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

The Usage of Treating Inflammation and Cancer for Natural Compound Garcimultiflorine E from Garcinia Esculenta Y.H. Li

總結
This invention relates to use a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound Garcimultiflorone E (GE), that is naturally occurring in the plant of Garcinia esculenta Y. H. Li has biological activity of potent anti-inflammation and anti-cancer effect.
技術優勢
The compound of the invention is useful for its anti-inflammatory and anti-tumor effects, and provides the candidate for anti-inflammatory and anti-cancer drugs.
技術應用
The novel compound may have potential to be developed as anticancer drug.
詳細技術說明
Garcinia esculenta Y. H. Li belongs to Garcinia genus of plants. It is one of endemic plants in China, which mainly grew up in the valley and areas above 860-1650 m sea level, and has not been artificially cultivated. Matured fruit is edible.
附加資料
Inventor: SHUM, Daisy Kwok Yan | IP, Mary Sau Man | CHAN, Chi Hang | LEUNG, Valeria On Yue
Priority Number: WO2011103774A1
IPC Current: A61K0031727 | A61K000912 | A61K000914 | A61P001100 | A61P001102
Assignee Applicant: The University of Hong Kong
Title: PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MANUFACTURING MEDICAMENTS FOR TREATING RESPIRATORY DISEASES | COMPOSITION PHARMACEUTIQUE ET UTILISATION DE CELLE-CI DANS LA FABRICATION DE MÉDICAMENTS POUR TRAITER DES MALADIES RESPIRATOIRES
Usefulness: PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MANUFACTURING MEDICAMENTS FOR TREATING RESPIRATORY DISEASES | COMPOSITION PHARMACEUTIQUE ET UTILISATION DE CELLE-CI DANS LA FABRICATION DE MÉDICAMENTS POUR TRAITER DES MALADIES RESPIRATOIRES
Summary: The composition is useful for treating a respiratory disease or disorder, such as one or more symptom of chronic respiratory inflammation and chronic respiratory inflammation including bronchiectasis, emphysema and chronic obstructive pulmonary disease, where the symptoms are prolonged or abnormal inflammation, permanently dilated bronchi, airflow limitation, chronic cough, sputum production, hemoptysis, dyspnea, air trapping, wheezing, chest pain or recurrent lung infection (all claimed). The composition is useful for treating e.g. vascular diseases including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis, mixed connective tissue disorder, vasculitis and sarcoid. Tests details are described but no results given.
Novelty: Composition, useful for treating respiratory disease e.g. chronic respiratory inflammation e.g. bronchiectasis and chronic obstructive pulmonary disease, comprises a agent to decrease neutrophil elastase activity in subject
主要類別
生物醫學
細分類別
醫藥成分
申請日期
2013.01.10
申請號碼
10/1/2013 (US 61/750,887)
其他
Filed
ID號碼
A61/BZ/Garc/US0P
國家/地區
香港

欲了解更多信息,請點擊 這裡
移動設備